Biosimilars have the potential to deliver substantial savings to the healthcare system, but only insofar as they are adopted and used in clinical practice. A newly published systematic review evaluated US and European healthcare provider knowledge, perceptions, and prescribing behaviors related to biosimilars, and it found that providers are still taking a cautious approach to biosimilars in part because of a lack of awareness of these medicines.
Biosimilars have the potential to deliver substantial savings to the healthcare system, but only insofar as they are adopted and used in clinical practice. A newly published systematic review evaluated US and European healthcare provider knowledge, perceptions, and prescribing behaviors related to biosimilars, and it found that providers are still taking a cautious approach to biosimilars in part because of a lack of awareness of these medicines.
The review, conducted by researchers from the University of North Carolina at Chapel Hill and Premier, Inc, relied on data derived from 20 surveys, published between 2014 and 2017, originating from the United States, Belgium, France, Germany, Italy, Ireland, Malta, Hungary, and the United Kingdom.
In total, 16 of the studies addressed providers’ biosimilar prescribing habits. One 2014 study found that 61% of gastroenterologists had little or no confidence in biosimilars, while a 2016 study found that just 7% of rheumatologists had prescribed a biosimilar. A 2016 study found that 51% of providers limited biosimilars to biologic-naïve patients. Limited biosimilar use in small patient groups was also reported by 38% of respondents in a 2017 survey, and another 2017 study found that 95% of providers preferred to use an originator product versus a biosimilar as first-line therapy for inflammatory diseases.
Providers reported that self-study and literature available in peer-reviewed journals and/or professional guidelines were the most trusted sources of biosimilar information in the United States and Europe. However, the researchers wrote, an overall lack of awareness about biosimilars persists in both the United States and Europe, with only 22.9% of physicians and 38.8% of pharmacists reporting “complete” or “good” knowledge of biosimilars in a 2016 survey. A 2017 survey of dermatologists found that 27% of providers said they had a “complete” understanding of biosimilars, but, concerningly, 21% of that group described biosimilars incorrectly.
Clinicians also reported having concerns about biosimilars, primarily related to immunogenicity. A 2016 survey found that 23% of providers believed biosimilars to have a higher risk of immunogenicity than reference products, and more than 60% of providers in a 2017 survey reported similar concerns about immunogenicity.
Providers also took issue with biosimilars’ safety and efficacy in extrapolated indications, with over 39% of rheumatologists in a 2017 survey objecting to the extrapolation of indications for biosimilars.
Another area of concern and lack of awareness among providers is interchangeability and pharmacy-level substitution; In 2016, 89.9% of surveyed clinicians disagreed with pharmacy-level substitution of a biosimilar, and in another 2016 survey, 80% of respondents were unaware that an interchangeability designation could result in automatic substitution.
“Findings from this study indicate that clinicians in the United States and Europe are cautious about biosimilar use and do not predominantly support the use of biosimilars as safe and effective treatment options in patients already receiving bio-originator therapy,” wrote the authors, adding that “biosimilar-specific education remains a relatively neglected area of emphasis in the published literature.” The authors suggest that educational efforts focus on the major areas of immunogenicity, extrapolation, and interchangeability to build awareness and confidence among providers.
Reference
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102-112. doi: 10.18553/jmcp.2019.25.1.102.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.